Last reviewed · How we verify

Humanity and Health Research Centre — Portfolio Competitive Intelligence Brief

Humanity and Health Research Centre pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SOF+DCV SOF+DCV marketed Other
SOF+PEG+RBV SOF+PEG+RBV marketed Other
SOF+RBV SOF+RBV marketed Direct-acting antiviral (DAA) combination HCV NS5B RNA polymerase; viral replication machinery Virology / Hepatology
Tenofovir alafenamide(TAF) Tenofovir alafenamide(TAF) marketed Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Almaza Military Fever Hospital · 1 shared drug class
  3. Egyptian Liver Hospital · 1 shared drug class
  4. Federal University of São Paulo · 1 shared drug class
  5. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  6. HaEmek Medical Center, Israel · 1 shared drug class
  7. Hannover Medical School · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Humanity and Health Research Centre:

Cite this brief

Drug Landscape (2026). Humanity and Health Research Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/humanity-and-health-research-centre. Accessed 2026-05-18.

Related